Ultragenyx Pharmaceutical Inc. (RARE) investor relations documents from the company's IR site: 1 presentation, 4 press releases; latest deck 2022-10-04. Read in-app with summaries. First-party data.
Our Commitment to Patients: Ultragenyx is a biopharmaceutical company focused on rare diseases, where 90% of its 18 targeted programs lack existing approved therapies.
| Published | Type | Document |
|---|---|---|
| 2026-08-04 | Press release | Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update |
| 2026-07-28 | Press release | Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update |
| Press release | Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update | |
| Press release | Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update | |
| 2022-10-04 | Presentation | Our Commitment to Patients |
RARE overview · RARE earnings · RARE financials · RARE KPIs · RARE documents · RARE ownership · RARE peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.